Flavoxate Uses, Dosage, Side Effects & Price | DrugsAtlas
Authoritative Clinical Reference
Navigation
DRUG NAME: Flavoxate
Therapeutic Class: Urological Agent
Subclass: Urinary Antispasmodic
Speciality: Urology
Schedule (India): Schedule H
Route(s): Oral
Formulations Available in India:
- Tablets: 100 mg
- Tablets: 200 mg
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
1. Symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, and urinary frequency associated with lower urinary tract conditions
Applicable conditions include:
- Cystitis (infectious or interstitial)
- Prostatitis
- Urethritis
- Urethrocystitis
- Urethrotrigonitis
- Post-operative bladder spasms
- Catheter-induced bladder irritation
| Parameter | Detail |
| Starting dose | 100–200 mg orally three times daily |
| Titration | Once symptoms improve, may reduce frequency to twice daily |
| Usual maintenance dose | 200 mg three times daily (or 100 mg TID–QID) |
| Maximum dose | 200 mg four times daily (800 mg/day) |
| Duration | Short-term use only (typically 3–7 days); reassess if symptoms persist beyond 7 days |
| Key clinical notes | Flavoxate provides symptomatic relief only — does not treat underlying infection. Always evaluate and treat underlying pathology (UTI, structural abnormality). Not intended for long-term monotherapy. |
Secondary Indications — Adults Only (Off-label, if any)
No well-documented off-label indications in Indian clinical practice.
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
Symptomatic relief of irritative lower urinary tract symptoms associated with UTI or post-instrumentation cystitis
(Paediatric urologist or paediatrician supervision recommended)
(Paediatric urologist or paediatrician supervision recommended)
| Age Group | Dose | Notes |
| Below 12 years |
NOT RECOMMENDED — insufficient safety and efficacy data
|
Do not prescribe except under exceptional specialist circumstances |
| 12 years and above | 100 mg orally three times daily | Same as adult dosing; limit duration to 5–7 days |
Safety monitoring in adolescents:
- Watch for anticholinergic effects: dry mouth, constipation, urinary retention, blurred vision
- Monitor for CNS effects: dizziness, drowsiness
- Ensure underlying infection is appropriately treated with antimicrobials
Secondary Indications — Paediatric Doses (Off-label, if any)
Not applicable.
Clear statement: Not recommended below 12 years of age except under close specialist supervision with documented justification.
RENAL ADJUSTMENT
| Renal Function | Recommendation |
| Mild impairment (eGFR 60–89) | No dose adjustment required |
| Moderate impairment (eGFR 30–59) | Use with caution; consider reduced dosing frequency (e.g., BID instead of TID) |
| Severe impairment (eGFR <30) | Avoid use — limited data on safety; drug clearance may be reduced |
| Haemodialysis | No data available; avoid if possible |
HEPATIC ADJUSTMENT
| Severity | Recommendation |
| Mild impairment (Child-Pugh A) | No dose adjustment required |
| Moderate impairment (Child-Pugh B) | Use with caution; no specific dose reduction data available |
| Severe impairment (Child-Pugh C) | Avoid use — insufficient safety data; hepatic metabolism may be impaired |
CONTRAINDICATIONS
- Known hypersensitivity to flavoxate or any excipient in the formulation
- Pyloric or duodenal obstruction
- Obstructive intestinal lesions or paralytic ileus
- Achalasia cardia
- Gastrointestinal haemorrhage
- Lower urinary tract obstruction with significant residual urine or high risk of urinary retention
- Obstructive uropathies
CAUTIONS
- Elderly patients — heightened susceptibility to anticholinergic adverse effects (dry mouth, constipation, confusion, urinary retention)
- Benign prostatic hyperplasia — monitor post-void residual; risk of precipitating acute retention
- Narrow-angle glaucoma (suspected or confirmed) — may worsen intraocular pressure
- Myasthenia gravis — may exacerbate muscle weakness
- Cardiac arrhythmias — tachycardia risk with anticholinergic effects
- Hiatal hernia with reflux oesophagitis
- Autonomic neuropathy
- Hot weather or high fever — impaired sweating may lead to heat stroke
- Cognitive impairment or dementia — may worsen confusion
- May mask symptoms of underlying urinary tract infection or structural pathology — always investigate the primary cause before prescribing
PREGNANCY
| Parameter | Detail |
| Overall safety | Insufficient human data; avoid unless clearly necessary |
| Risk category | Not formally classified in India; animal studies have not shown teratogenicity but human data lacking |
| Preferred alternatives | Supportive measures (hydration, heat packs); treat underlying UTI with pregnancy-safe antibiotics; phenazopyridine may be considered for short-term dysuria relief in 2nd/3rd trimester (specialist input) |
| When it may be used | Only if benefit clearly outweighs risk; avoid in first trimester |
| What to monitor | Fetal well-being; maternal symptoms of urinary retention |
LACTATION
| Parameter | Detail |
| Compatibility | Caution advised — insufficient data on excretion into human breast milk |
| Expected drug levels in milk | Likely low (based on pharmacokinetic profile), but not confirmed |
| Preferred alternatives | Supportive care; treat underlying infection with lactation-compatible antibiotics; avoid prolonged use of urinary antispasmodics during breastfeeding |
| What to monitor in infant | Sedation, poor feeding, irritability, dry mouth, constipation |
| Recommendation | Use only when clearly necessary and for the shortest possible duration |
ELDERLY
- Recommended starting dose: 100 mg twice daily (lower end of dosing range)
- Titration: Increase cautiously to TID only if tolerated and clinically necessary
- Extra risks:
-
- Higher sensitivity to anticholinergic burden — dry mouth, constipation, urinary retention, blurred vision
- CNS effects — confusion, cognitive impairment, drowsiness, dizziness (fall risk)
- Worsening of pre-existing dementia symptoms
- Tachycardia in patients with cardiovascular disease
- Exacerbation of benign prostatic hyperplasia symptoms
- General guidance: Limit duration of use; reassess necessity frequently; consider non-pharmacological approaches where possible
MAJOR DRUG INTERACTIONS
| Interacting Drug/Class | Effect / Risk | Action |
| Other anticholinergic agents (oxybutynin, tolterodine, solifenacin, antihistamines, tricyclic antidepressants, antipsychotics) | Additive anticholinergic burden — increased risk of dry mouth, constipation, urinary retention, confusion, cognitive impairment, tachycardia | Avoid concurrent use unless essential; if combined, monitor closely for anticholinergic toxicity |
| Potassium chloride (solid oral formulations) | Delayed gastric emptying from anticholinergic effect may increase contact time with GI mucosa → risk of mucosal ulceration | Avoid concurrent use with solid KCl; use liquid potassium preparations if supplementation needed |
MODERATE DRUG INTERACTIONS
| Interacting Drug/Class | Effect / Risk | Action |
| CNS depressants (benzodiazepines, opioids, sedating antihistamines, alcohol) | Additive sedation and drowsiness | Use with caution; warn about driving and operating machinery |
| Drugs dependent on gastric motility for absorption (e.g., levodopa, certain antibiotics) | Slowed GI transit may alter absorption kinetics | Monitor clinical response; adjust timing of administration if needed |
| Metoclopramide, domperidone | Opposing effects on GI motility — flavoxate may reduce prokinetic efficacy | Avoid combination where possible; if used together, monitor for therapeutic failure of prokinetic |
| Acetylcholinesterase inhibitors (donepezil, rivastigmine) | Pharmacological antagonism — may reduce efficacy of both agents | Avoid concurrent use if possible; if combined, monitor cognitive status closely |
COMMON ADVERSE EFFECTS
- Dry mouth (most frequent)
- Nausea and vomiting
- Abdominal discomfort
- Headache
- Drowsiness
- Dizziness
- Blurred vision
- Nervousness
SERIOUS ADVERSE EFFECTS
- Acute urinary retention — especially in patients with prostatic enlargement or pre-existing voiding dysfunction → discontinue immediately; may require catheterisation
- Acute confusional state / delirium — particularly in elderly patients → discontinue and evaluate
- Tachycardia and palpitations — may exacerbate underlying cardiac conditions
- Paralytic ileus (rare) — presents with abdominal distension, absent bowel sounds → discontinue immediately; surgical consultation may be required
- Hypersensitivity reactions (urticaria, angioedema, rash) — discontinue and provide supportive care
- Leucopenia (rare) — reported in post-marketing surveillance
- Elevated intraocular pressure — risk in patients with undiagnosed narrow-angle glaucoma
MONITORING REQUIREMENTS
Baseline (before starting):
- Urinary symptom assessment (frequency, urgency, dysuria, nocturia)
- Post-void residual urine volume (especially in males with prostatic symptoms)
- Urine examination to rule out or confirm infection
- Review of anticholinergic burden from concomitant medications
After initiation:
- Reassess symptoms within 3–5 days
- Monitor for urinary retention (especially in elderly or patients with prostatic enlargement)
- Assess for anticholinergic side effects (dry mouth, constipation, confusion)
Long-term (if used beyond 7 days):
- Re-evaluate need for continued therapy
- Ensure underlying pathology has been adequately addressed
- Monitor cognitive function in elderly patients
BRANDS AVAILABLE IN INDIA
- Urispas 100 mg / 200 mg tablets (Abbott / Pfizer)
- Flavospas 100 mg tablets (Synokem)
- Vospas 100 mg tablets (Elder Pharmaceuticals)
- Urocare 200 mg tablets (Alkem)
- Genurin 200 mg tablets (available in some regions)
(No commonly marketed fixed-dose combinations with flavoxate in India)
PRICE RANGE (INR)
- Flavoxate 100 mg tablet: ₹5–10 per tablet (varies by brand)
- Flavoxate 200 mg tablet: ₹8–15 per tablet (varies by brand)
- Not listed under NLEM; not under NPPA price control
- Availability in government facilities depends on institutional formulary inclusion
CLINICAL PEARLS
- Symptomatic agent only: Flavoxate provides relief from urinary urgency, frequency, and dysuria but does NOT treat the underlying infection or pathology. Always investigate and treat the primary cause (UTI, prostatitis, structural abnormality).
- Short-term use: Limit prescribing to 5–7 days in most cases. Prolonged use without addressing underlying pathology is inappropriate.
- Elderly caution: The anticholinergic burden makes flavoxate a poor choice for older patients, especially those with cognitive impairment, constipation, or prostatic symptoms. Consider alternatives or use lowest effective dose for shortest duration.
- Catheter-related discomfort: Flavoxate is useful for bladder spasms associated with indwelling catheters or post-urological instrumentation, but ensure catheter position and patency are adequate before attributing symptoms to spasm alone.
- Not a substitute for antimuscarinics in OAB: For chronic overactive bladder, agents like oxybutynin, tolterodine, or solifenacin are preferred for long-term management. Flavoxate lacks robust evidence for sustained OAB treatment.
- Differentiate from phenazopyridine: Phenazopyridine is a urinary analgesic (colours urine orange) useful for dysuria relief; flavoxate is an antispasmodic. They have different mechanisms and indications — do not use interchangeably.
TAGS
flavoxate; urinary antispasmodic; dysuria; urgency; frequency; bladder spasm; catheter discomfort; cystitis; elderly caution; anticholinergic; Schedule H; urology
VERSION
RxIndia v0.1 — 14 Feb 2026
REFERENCES
- CDSCO: Approved product monographs for flavoxate formulations
- IP/NFI: Flavoxate listed in National Formulary of India
- NLEM: Not listed
- Manufacturer product inserts: Abbott/Pfizer India (Urispas)
- API Textbook of Medicine: Urinary tract infection and lower urinary tract symptom management (supportive reference)
- AIIMS Hospital Formulary: Supportive reference for dosing and indications
- Goodman & Gilman’s The Pharmacological Basis of Therapeutics: Pharmacology of smooth muscle relaxants
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.